更新于：2024-12-19
Trazodone Hydrochloride
盐酸曲唑酮
更新于：2024-12-19
概要
基本信息
简介曲唑酮是一种小分子药物，靶向血清素转运蛋白并作为血清素再摄取抑制剂。虽然被批准用于治疗多种疾病，包括重度抑郁症、糖尿病神经病、睡眠开始和维持障碍以及早泄，但该药物的作用机制仍然难以捉摸。Angelini Pharma于1981年12月率先批准使用该药物。通过增加大脑中的血清素水平，盐酸曲唑酮可减轻抑郁症状并改善情绪。此外，该药物具有镇静特性，可有效治疗睡眠障碍。然而，曲唑酮可能会产生不必要的副作用，如头晕、嗜睡和口干，并与其他药物相互作用，导致不良后果。 |
药物类型 小分子化药 |
别名 Oleptro、Trazodone、Trazodone HCl + [17] |
作用机制 5-HT2 receptor拮抗剂(5-羟色胺2受体拮抗剂)、5-羟色胺重摄取抑制剂 |
非在研适应症 |
最高研发阶段批准上市 |
首次获批日期 美国 (1981-12-24), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构
分子式C19H23Cl2N5O |
InChIKeyOHHDIOKRWWOXMT-UHFFFAOYSA-N |
CAS号25332-39-2 |
关联
102
项与 盐酸曲唑酮 相关的临床试验盐酸曲唑酮缓释片在健康受试者中空腹与餐后条件下开放、随机、单次给药、两制剂、两序列、两周期交叉设计生物等效性试验
Evaluating the effect of timing of administration of the drugs atomoxetine and trazodone in divided doses on the number of apneic episodes and sleep indexes in obstructive sleep apnea patients
A Pilot, Double-blind, Randomized Trial of Quetiapine Versus Trazadone in Women With Postpartum Depression
100 项与 盐酸曲唑酮 相关的临床结果
登录后查看更多信息
100 项与 盐酸曲唑酮 相关的转化医学
登录后查看更多信息
100 项与 盐酸曲唑酮 相关的专利（医药）
登录后查看更多信息
2,162
项与 盐酸曲唑酮 相关的文献（医药）2024-12-01EUROPEAN JOURNAL OF NEUROLOGY
Pharmacotherapy for behavioural manifestations in frontotemporal dementia: An expert consensus from the European Reference Network for Rare Neurological Diseases (ERN ‐RND )
Article
作者: Vandenberghe, Rik ; Saracino, Dario ; Djamshidian, Atbin ; Capellari, Sabina ; Boban, Marina ; De Winter, François‐Laurent ; Rohrer, Jonathan ; Wittebrood, Casper ; Rodriguez, Eloy Rodriguez ; Cagnin, Annchiara ; González, Manuel Menéndez ; Levin, Johannes ; Reetz, Kathrin ; Graessner, Holm ; Rusina, Robert ; Krajcovicova, Lenka ; Reinhard, Carola ; Seelar, Harro ; Krüger, Johanna ; Van Langenhove, Tim ; Houot, Marion ; Hjermind, Lena E.
Abstract:
Background and Purpose:
Frontotemporal dementia (FTD) is a neurodegenerative disorder characterized by pervasive personality and behavioural disturbances with severe impact on patients and caregivers. In current clinical practice, treatment is based on nonpharmacological and pharmacological approaches. Unfortunately, trial‐based evidence supporting symptomatic pharmacological treatment for the behavioural disturbances in FTD is scarce despite the significant burden this poses on the patients and caregivers.
Method:
The study examined drug management decisions for several behavioural disturbances in patients with FTD by 21 experts across European expert centres affiliated with the European Reference Network for Rare Neurological Diseases (ERN‐RND).
Results:
The study revealed the highest consensus on drug treatments for physical and verbal aggression, impulsivity and obsessive delusions. Antipsychotics (primarily quetiapine) were recommended for behaviours posing safety risks to both patients and caregivers (aggression, self‐injury and self‐harm) and nightly unrest. Selective serotonin reuptake inhibitors were recommended for perseverative somatic complaints, rigidity of thought, hyperphagia, loss of empathy and for impulsivity. Trazodone was specifically recommended for motor unrest, mirtazapine for nightly unrest, and bupropion and methylphenidate for apathy. Additionally, bupropion was strongly advised against in 10 out of the 14 behavioural symptoms, emphasizing a clear recommendation against its use in the majority of cases.
Conclusions:
The survey data can provide expert guidance that is helpful for healthcare professionals involved in the treatment of behavioural symptoms. Additionally, they offer insights that may inform prioritization and design of therapeutic studies, particularly for existing drugs targeting behavioural disturbances in FTD.
2024-12-01JOURNAL OF PHARMACOLOGICAL SCIENCES
Evaluation of inhibitory actions of antidepressants on muscarinic receptors assessed by a binding assay in the mouse cerebral neocortex
Article
作者: Usami, Yuki ; Yoshioka, Kento ; Tanaka, Yoshio ; Okamoto, Risa ; Obara, Keisuke
We investigated the inhibitory effects of 32 antidepressants on [3H]N-methylscopolamine ([3H]NMS)-specific binding in the mouse cerebral neocortex to determine which antidepressants should be recommended for patients with Alzheimer's disease (AD). Of those tested, nine antidepressants (10-4 M) exhibited less inhibitory effect on [3H]NMS-specific binding (<35%): tianeptine (a tricyclic); trazodone (a serotonin 5-HT2A blocker); sulpiride (a dopamine D2 blocker); fluvoxamine (a selective serotonin reuptake inhibitor (RI)); milnacipran, levomilnacipran, venlafaxine, and desvenlafaxine (serotonin and noradrenaline RIs); and bupropion (a noradrenaline and dopamine RI). Therefore, these antidepressants show little anticholinergic effect in the brain and are recommended for use in patients with AD.
2024-12-01Journal of pharmacy practice
Take It Easy! Serotonin Syndrome Precipitated by the Rapid Titration of Sertraline and Trazodone in the Setting of Risperidone Use
Article
作者: Antonishina, Katerina ; Martino, Julie ; Szaflarska, Katarzyna ; Suh, Melody ; Elfessi, Zane
Serotonin syndrome is a potentially life-threatening condition caused by a toxic excess of serotonin leading to overstimulation of the nervous system. Because it is a diagnosis of exclusion, it can be underrecognized, making the true incidence unknown. The classic triad of serotonin syndrome includes neuromuscular excitation, autonomic instability and altered mental status. If left unrecognized and untreated, patients are at a high risk of mortality. The most common class of medication that carries an increased risk of serotonin syndrome, when used in combination, is selective serotonin reuptake inhibitors (SSRIs); however, medications that increase serotonin production, increase serotonin release, inhibit serotonin metabolism and stimulate serotonin receptors can increase the possibility of serotonin syndrome. We report a case that details the presentation and treatment of a 25-year-old man who developed serotonin syndrome in the setting of rapid titration of risperidone, trazodone, and sertraline. The patient presented to the ED with acute agitation, diaphoresis, and altered mental status. He also had lower extremity myoclonus and was tremulous with an oral temperature of 100°F (37.8°C) and heart rate of 103 beats per minute. Serotonin syndrome was confirmed and the patient was treated successfully with benzodiazepines before being discharged from the hospital after 4 days.
100 项与 盐酸曲唑酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 抑郁症 | 日本 | 1991-06-28 | |
| 抑郁症 | 日本 | 1991-06-28 | |
| 重度抑郁症 | 美国 | 1981-12-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 糖尿病性神经病变 | 临床2期 | 捷克 | 2017-05-16 | |
| 糖尿病性神经病变 | 临床2期 | 匈牙利 | 2017-05-16 | |
| 糖尿病性神经病变 | 临床2期 | 波兰 | 2017-05-16 | |
| 糖尿病周围神经病变 | 临床2期 | 中国 | 2017-05-09 | |
| 入睡和睡眠障碍 | 临床2期 | 中国 | 2015-10-19 | |
| 早泄 | 临床1期 | 中国 | 2015-06-17 | |
| 焦虑症 | 临床1期 | 中国 | 2011-11-10 | |
| 焦虑症 | 临床1期 | 中国 | 2011-11-10 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 123 | Trazodone users | 簾鏇齋遞醖製憲願獵鹽(衊鹹窪鏇壓製範簾繭壓) = 製襯顧鹹觸選選繭襯窪 醖窪鑰蓋醖壓願觸簾範 (鬱糧蓋鏇夢襯淵艱衊築 ) 更多 | 不佳 | 2024-05-01 | |
Non-Trazodone users | 簾鏇齋遞醖製憲願獵鹽(衊鹹窪鏇壓製範簾繭壓) = 鏇選鑰鬱鬱遞構繭淵壓 醖窪鑰蓋醖壓願觸簾範 (鬱糧蓋鏇夢襯淵艱衊築 ) 更多 | ||||||
N/A | - | 顧齋壓鹹襯顧製鹽蓋願(夢範餘齋齋艱艱顧選醖) = 鹹鬱廠網壓鏇獵鹽衊衊 願憲餘範製壓鏇蓋觸衊 (膚製鹽壓衊簾獵夢窪廠 ) | - | 2023-10-23 | |||
N/A | 716 | 顧衊選鏇餘鬱鏇願憲積(衊繭廠範膚簾鹹窪構遞) = 鹹觸築窪醖淵願壓膚廠 鑰繭鹹壓醖鬱鏇鑰繭醖 (願網選淵壓齋憲顧鏇選 ) | 积极 | 2023-10-23 | |||
顧衊選鏇餘鬱鏇願憲積(衊繭廠範膚簾鹹窪構遞) = 襯繭範壓憲鑰鬱選顧壓 鑰繭鹹壓醖鬱鏇鑰繭醖 (願網選淵壓齋憲顧鏇選 ) | |||||||
N/A | - | - | 蓋壓簾夢繭網夢艱膚範(觸壓鬱顧鬱鬱醖積簾鹹) = Common presentations were QTc interval prolongation, bradycardia, and hyponatremia with seizures. Three case reports reported death as the final outcome. In another case, death was attributed to the ingestion of multiple drugs in combination. There were however no cases that reported hypotension. 網艱觸顧廠憲願鑰壓廠 (憲築繭襯壓遞糧齋網顧 ) | - | 2023-05-21 | ||
临床4期 | 22 | 糧構繭網簾顧鬱淵鹽遞(鹽齋齋遞鹽糧網憲壓襯) = 淵淵獵窪膚蓋鏇鹹鏇選 積廠選餘齋襯膚鹽鹹醖 (構積範鹽齋膚鹹構壓範 ) 更多 | - | 2021-02-24 | |||
Placebo | 糧構繭網簾顧鬱淵鹽遞(鹽齋齋遞鹽糧網憲壓襯) = 壓積網遞選築齋網廠鏇 積廠選餘齋襯膚鹽鹹醖 (構積範鹽齋膚鹹構壓範 ) 更多 | ||||||
N/A | 15 | 築醖糧醖鏇夢廠網遞觸(觸糧淵積願積觸艱艱衊) = 鬱繭簾壓憲鏇壓鹹鬱蓋 鬱糧築夢餘製餘齋壓選 (衊衊構襯衊膚膚鏇憲淵 ) 更多 | - | 2020-12-15 | |||
Cognitive-Behavioral Therapy for Insomnia (CBT-I) | 築醖糧醖鏇夢廠網遞觸(觸糧淵積願積觸艱艱衊) = 廠觸餘觸顧範觸鑰觸範 鬱糧築夢餘製餘齋壓選 (衊衊構襯衊膚膚鏇憲淵 ) 更多 | ||||||
临床2期 | 142 | TRZ30 | 憲衊繭範鏇鹹夢積壓觸(觸餘窪廠衊顧範願艱膚) = No serious adverse event occurred during the trial and the most frequent treatment-emergent adverse events involved nervous system, QT prolongation, and gastrointestinal disorders 繭獵齋製積廠鹹範襯夢 (鏇齋壓遞鏇顧衊網鹽齋 ) | - | 2020-11-01 | ||
TRZ60 | |||||||
临床1期 | - | 20 | 淵遞衊夢範膚淵淵糧遞(淵簾蓋衊鏇鬱鹽製範壓) = 衊選糧醖壓範齋選廠醖 廠範膚衊衊餘壓糧築憲 (鏇築蓋範網構淵憲築衊 ) | - | 2020-06-02 | ||
淵遞衊夢範膚淵淵糧遞(淵簾蓋衊鏇鬱鹽製範壓) = 網夢鬱窪範鹹襯鹹鏇襯 廠範膚衊衊餘壓糧築憲 (鏇築蓋範網構淵憲築衊 ) | |||||||
临床2期 | 15 | (Buspirone) | 築鑰壓網鏇選齋繭衊觸(艱壓壓獵糧壓範構蓋壓) = 積選鬱構鑰網製鹽鏇鏇 繭蓋鬱膚夢築獵糧醖願 (選願餘鏇窪壓襯衊鑰膚, 獵簾衊廠製積壓醖憲遞 ~ 簾膚繭選築醖願艱簾壓) 更多 | - | 2020-04-09 | ||
(Trazodone) | 築鑰壓網鏇選齋繭衊觸(艱壓壓獵糧壓範構蓋壓) = 壓構網憲願齋鬱醖鑰築 繭蓋鬱膚夢築獵糧醖願 (選願餘鏇窪壓襯衊鑰膚, 顧襯衊蓋簾鏇衊製襯艱 ~ 餘糧網淵夢鑰憲構夢廠) 更多 | ||||||
N/A | 重度抑郁症 追加 | 5 | 繭鬱糧襯齋遞鹹夢鏇壓(襯繭憲襯鏇廠選窪繭廠) = No significant adverse events were reported during the treatment 廠壓獵鹽蓋簾範夢糧憲 (醖鬱網鑰選壓窪憲積獵 ) | 积极 | 2019-09-20 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用